<?xml version="1.0" encoding="UTF-8"?>
<p>Regarding ability to report on comorbidities, respondents in three countries (Estonia, Italy, and Turkey) reported that the countries could not monitor any of the four specified aspects (testing/screening offer, uptake, diagnosis, or treatment) of 12 of the 17 comorbidities (
 <xref rid="T2" ref-type="table">Table 2</xref>). The comorbidities reported to be most comprehensively monitored by study countries were drug dependence, hepatitis B virus, hepatitis C virus, and tuberculosis. The comorbidities reported to be least comprehensively monitored were anxiety, chronic pain syndrome and depression, all of which could only be monitored by Slovenia and Sweden. There were no comorbidities that all six countries were reported to be able to monitor.
</p>
